MARX Biotech Co., Ltd.
MARX Biotech Co., Ltd. engages in the online retail of men's health food and cosmeceutical products. The company was founded in 2015 and is based in New Taipei City, Taiwan.
MARX Biotech Co., Ltd. (7731) - Total Liabilities
Latest total liabilities as of June 2025: NT$519.21 Million TWD
Based on the latest financial reports, MARX Biotech Co., Ltd. (7731) has total liabilities worth NT$519.21 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
MARX Biotech Co., Ltd. - Total Liabilities Trend (2021–2024)
This chart illustrates how MARX Biotech Co., Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
MARX Biotech Co., Ltd. Competitors by Total Liabilities
The table below lists competitors of MARX Biotech Co., Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Daemyoung Energy Co Ltd
KQ:389260
|
Korea | ₩235.98 Billion |
|
Pulse Seismic Inc
OTCQX:PLSDF
|
USA | $7.30 Million |
|
Geodrill Ltd
F:7GD
|
Germany | €49.18 Million |
|
DP Cap Acquisition I Corp
NASDAQ:DPCS
|
USA | $14.04 Million |
|
Pullup Entertainment Société anonyme
PA:ALPUL
|
France | €231.23 Million |
|
SanDi Properties Co Ltd
TW:1438
|
Taiwan | NT$11.45 Billion |
|
Metro Ticari ve Mali Yatirimlar Holding AS
IS:METRO
|
Turkey | TL238.61 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down MARX Biotech Co., Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.71 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how MARX Biotech Co., Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for MARX Biotech Co., Ltd. (2021–2024)
The table below shows the annual total liabilities of MARX Biotech Co., Ltd. from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$479.95 Million | +371.20% |
| 2023-12-31 | NT$101.86 Million | +139.92% |
| 2022-12-31 | NT$42.45 Million | +66.74% |
| 2021-12-31 | NT$25.46 Million | -- |